在刚果民主共和国，美拉胂醇治疗昏睡病的失败率很高。
High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo.
作者信息
Robays Jo, Nyamowala Gaspard, Sese Claude, Betu Ku Mesu Kande Victor, Lutumba Pascal, Van der Veken Wim, Boelaert Marleen
机构信息
Institute of Tropical Medicine, Antwerp, Belgium.
出版信息
Emerg Infect Dis. 2008 Jun;14(6):966-7. doi: 10.3201/eid1406.071266.
Abstract
A retrospective chart review of 4,925 human African trypanosomiasis patients treated with melarsoprol in 2001-2003 in Equateur Nord Province of the Democratic Republic of Congo showed a treatment failure rate of 19.5%. This rate increased over the 3 years. Relapse rates were highest in the central part of the province.
摘要
对2001年至2003年在刚果民主共和国赤道北省接受美拉胂醇治疗的4925例人类非洲锥虫病患者进行的回顾性病历审查显示，治疗失败率为19.5%。该比率在3年中有所上升。该省中部的复发率最高。
相似文献
1
High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo.在刚果民主共和国，美拉胂醇治疗昏睡病的失败率很高。
Emerg Infect Dis. 2008 Jun;14(6):966-7. doi: 10.3201/eid1406.071266.
2
Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.1982年至2001年，刚果民主共和国，美拉胂醇治疗后锥虫病复发情况
Emerg Infect Dis. 2005 Jun;11(6):921-7. doi: 10.3201/eid1106.050036.
3
Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.美拉胂醇与依氟鸟氨酸治疗刚果共和国晚期冈比亚锥虫病的疗效比较
Bull World Health Organ. 2006 Oct;84(10):783-91. doi: 10.2471/blt.06.031955.
4
Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.晚期 2 期非洲人类锥虫病的死亡率趋势和危险因素：对刚果民主共和国 23 年经验的批判性评估。
PLoS Negl Trop Dis. 2018 Jun 13;12(6):e0006504. doi: 10.1371/journal.pntd.0006504. eCollection 2018 Jun.
5
Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.来自刚果民主共和国已治愈和复发昏睡病患者的布氏冈比亚锥虫分离株的美拉胂醇敏感性概况。
PLoS Negl Trop Dis. 2014 Oct 2;8(10):e3212. doi: 10.1371/journal.pntd.0003212. eCollection 2014 Oct.
6
Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.刚果共和国早期人类非洲锥虫病（HAT）患者的治疗结果及复发风险因素
Bull World Health Organ. 2006 Oct;84(10):777-82. doi: 10.2471/blt.05.028399.
7
Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.砷剂（美拉胂醇）、喷他脒和苏拉明用于治疗人类非洲锥虫病。
Parasitol Res. 2003 May;90(1):71-9. doi: 10.1007/s00436-002-0799-9. Epub 2003 Jan 31.
8
Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.冈比亚锥虫病：美拉胂醇治疗失败的频率及危险因素。
Trans R Soc Trop Med Hyg. 1994 Jul-Aug;88(4):447-52. doi: 10.1016/0035-9203(94)90430-8.
9
Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo.刚果民主共和国姆布吉-马伊疫区治疗失败的昏睡病患者中布氏冈比亚锥虫的群体遗传学
Infect Genet Evol. 2015 Mar;30:128-133. doi: 10.1016/j.meegid.2014.12.017. Epub 2014 Dec 20.
10
Randomized, controlled trial of treatments for second-stage sleeping sickness.二期昏睡病治疗的随机对照试验。
J Infect Dis. 2007 Aug 15;196(4):650-1. doi: 10.1086/519745.
引用本文的文献
1
Human African Trypanosomiasis (Sleeping Sickness)-Epidemiology, Clinical Manifestations, Diagnosis, Treatment, and Prevention.人类非洲锥虫病（昏睡病）——流行病学、临床表现、诊断、治疗及预防
Curr Trop Med Rep. 2023 Dec;10(4):222-234. doi: 10.1007/s40475-023-00304-w. Epub 2023 Oct 25.
2
New Series of Imidazoles Showed Promising Growth Inhibitory and Curative Potential Against Trypanosoma Infection.一系列新型咪唑类化合物在抑制和治疗锥虫感染方面显示出了良好的效果。
Yale J Biol Med. 2021 Jun 30;94(2):199-207. eCollection 2021 Jun.
3
Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.在刚果民主共和国，用硝呋替莫依氟苯隆组合疗法（NECT）治疗冈比亚锥虫病二期昏睡病患者时的伴随药物处方。
PLoS Negl Trop Dis. 2020 Jan 27;14(1):e0008028. doi: 10.1371/journal.pntd.0008028. eCollection 2020 Jan.
4
The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History.昏睡病的药物：其作用机制、耐药性及简史
Trop Med Infect Dis. 2020 Jan 19;5(1):14. doi: 10.3390/tropicalmed5010014.
5
A FRET flow cytometry method for monitoring cytosolic and glycosomal glucose in living kinetoplastid parasites.一种用于监测活的动质体寄生虫细胞溶质和糖质体葡萄糖的 FRET 流式细胞术方法。
PLoS Negl Trop Dis. 2018 May 31;12(5):e0006523. doi: 10.1371/journal.pntd.0006523. eCollection 2018 May.
6
A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.一项多中心、随机、非劣效性临床试验，比较了硝呋替莫-依氟鸟氨酸联合治疗与乌干达晚期布氏冈比亚锥虫人体非洲锥虫病的标准依氟鸟氨酸单药治疗。
Parasit Vectors. 2018 Feb 22;11(1):105. doi: 10.1186/s13071-018-2634-x.
7
Photo-affinity labelling and biochemical analyses identify the target of trypanocidal simplified natural product analogues.光亲和标记和生化分析确定了杀锥虫简化天然产物类似物的靶点。
PLoS Negl Trop Dis. 2017 Sep 5;11(9):e0005886. doi: 10.1371/journal.pntd.0005886. eCollection 2017 Sep.
8
Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity.水甘油通道蛋白缺失的锥虫表现出甘油转运缺陷和对呼吸抑制剂的敏感性。
PLoS Pathog. 2017 Mar 30;13(3):e1006307. doi: 10.1371/journal.ppat.1006307. eCollection 2017 Mar.
9
Drug resistance in eukaryotic microorganisms.真核微生物的耐药性。
Nat Microbiol. 2016 Jun 24;1(7):16092. doi: 10.1038/nmicrobiol.2016.92.
10
Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense.布氏罗得西亚锥虫耐药性的比较基因组学
Cell Mol Life Sci. 2016 Sep;73(17):3387-400. doi: 10.1007/s00018-016-2173-6. Epub 2016 Mar 14.
本文引用的文献
1
Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.依氟鸟氨酸是治疗安哥拉卡希托市第二阶段人类西非锥虫病的一种具有成本效益的替代药物，可替代美拉胂醇。
Trop Med Int Health. 2008 Feb;13(2):265-71. doi: 10.1111/j.1365-3156.2007.01999.x.
2
Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda.三种治疗晚期布氏冈比亚锥虫昏睡病的药物组合：乌干达的一项随机临床试验
PLoS Clin Trials. 2006 Dec 8;1(8):e39. doi: 10.1371/journal.pctr.0010039.
3
Trypanosomiasis control, Democratic Republic of Congo, 1993-2003.1993 - 2003年刚果民主共和国的锥虫病防治工作
Emerg Infect Dis. 2005 Sep;11(9):1382-8. doi: 10.3201/eid1109.041020.
4
Prospects for improving African trypanosomiasis chemotherapy.改善非洲锥虫病化疗的前景。
J Infect Dis. 2005 Jun 1;191(11):1793-5. doi: 10.1086/429935. Epub 2005 May 2.
5
The phenomenon of treatment failures in Human African Trypanosomiasis.人类非洲锥虫病治疗失败的现象
Trop Med Int Health. 2001 Nov;6(11):906-14. doi: 10.1046/j.1365-3156.2001.00775.x.
6
Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.来自乌干达西北部奥穆戈的对美拉胂醇耐药的布氏冈比亚锥虫。
Trop Med Int Health. 2001 May;6(5):407-11. doi: 10.1046/j.1365-3156.2001.00712.x.
7
The situation of sleeping sickness in Angola: a calamity.安哥拉昏睡病的情况：一场灾难。
Trop Med Int Health. 2001 May;6(5):330-4. doi: 10.1046/j.1365-3156.2001.00724.x.
8
[Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda].[乌干达晚期布氏冈比亚人体非洲锥虫病患者中美拉胂醇的治疗失败情况]
Bull Soc Pathol Exot. 1999 Jul;92(3):171-2.
Zotero 插件